Trial Profile
Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; K NK002 (Primary) ; Fludarabine; Melphalan
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus First in man; Proof of concept; Therapeutic Use
- Acronyms NK-REALM
- Sponsors CytoSen Therapeutics; Kiadis Pharma
- 16 Jun 2021 Status changed from active, no longer recruiting to withdrawn prior to enrolment.
- 23 Feb 2021 Planned End Date changed from 1 Mar 2023 to 1 Nov 2023.
- 23 Feb 2021 Planned primary completion date changed from 1 Dec 2022 to 1 Nov 2022.